On 19/5/2020 AVEXIS announced that “Zolgensma gene therapy received conditional approval from EMA for patients with Spinal Muscular Atrophy with a clinical diagnosis of SMA I or SMA with up to 3 copies of SMN2”
Below you may find the company’s Press Release, the Executive Decision of the European Commission translated into Greek and its Annexes which contain all the information about the drug.
AVEXIS-Press release-receives-ec-approval-for-zolgensma (1)
ZOLGENSMA Παραρτήματα απόφασης EC
AVEXIS Press release :
https://investors.avexis.com/news-releases/news-release-details/avexis-receives-ec-approval-for-zolgensma?fbclid=IwAR13we9-bCO5p_4j_puYDIu554rBxlpVXGvH1Xl3MJ8quey-9c6JXr_OMQM